BeiGene Q1 2024 revenue up 82% to $752M; BRUKINSA sales $489M

BeOne Medicines Ltd.

2024-Q1 EPS reported -$0.19 revenue$751,652,000

Total Q1 product revenue $747M (+82% YoY); total revenue $752M; BRUKINSA revenue $489M.
BRUKINSA U.S. sales grew 153% and Europe 243% YoY; fifth FDA approval gives broadest BTKi label.
GAAP operating loss narrowed to $261M from $371M; adjusted operating loss $147M vs $276M.
TEVIMBRA now approved in U.S. and Europe; advancing late-stage pipeline including sonrotoclax and BTK CDAC.
Company says progressing toward sustainable profitability with improved operating leverage.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BeOne Medicines Ltd. reported the three months ended March 31, 2024 results: revenue $752 million.

Period: the three months ended March 31, 2024
Revenue: $752 million
Result: reported results

Exact text from the filing

as Exhibit 99.1 to this Current Report on Form 8-K. --- EX-99.1 (EX-99.1) --- BeiGene Reports First Quarter 2024 Financial Results and Business Updates • Total revenues of $752 million in the first quarter, including product revenue of $747 million, an 82% increase from the prior-year period • BRUKINSA revenue of $489 million, driven by growth in the U.S. and

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

BeOne Medicines Ltd. filing history →

Source: SEC EDGAR

accession 0001651308-24-000049

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.